Home › Cases › Primary Sclerosing Cholangitis
Ascending Cholangitis
Primary Sclerosing Cholangitis
6 questions
Question 1 · PSC features
Correct answer: Primary sclerosing cholangitis (PSC) — male, IBD (UC 70%), beaded ducts on MRCP, elevated ALP
Why
PSC features: young-middle-aged male, associated with IBD (UC in 70-80%), fibro-inflammatory strictures of bile ducts → beaded appearance on MRCP. ALP elevated. Pruritus. Complications: dominant strictures, recurrent cholangitis, cholangiocarcinoma (10-15% lifetime risk), cirrhosis, hepatocellular carcinoma. No medical treatment slows progression.
Key point
PSC: young male + UC + beaded ducts on MRCP + raised ALP. 10-15% lifetime cholangiocarcinoma risk. No proven treatment.
Question 2 · PBC vs PSC
Correct answer: PBC: middle-aged women, AMA (anti-mitochondrial antibody) positive, small intrahepatic ducts, responds to UDCA. PSC: younger males, UC association, intra+extra ductal involvement, AMA negative
Why
PBC vs PSC: PBC (Primary Biliary Cholangitis — formerly PBC): middle-aged women, AMA positive (>95%), intrahepatic small bile duct involvement only, responds to ursodeoxycholic acid (UDCA). PSC: younger males, AMA negative, IBD, large and small duct involvement, MRCP beaded pattern, no proven medical therapy.
Key point
PBC: women + AMA positive + responds to UDCA. PSC: men + UC + AMA negative + beaded MRCP. UDCA has no proven benefit in PSC.
Question 3 · Cholangiocarcinoma surveillance
Correct answer: Annual MRCP + serum CA19-9. Urgently investigate: dominant stricture, worsening liver function, new symptoms — high index of suspicion for CCA
Why
PSC cholangiocarcinoma (CCA) surveillance: EASL recommends annual MRCP and serum CA19-9. CCA risk 10-15% lifetime — median 5.5 years from PSC diagnosis. CCA is difficult to differentiate from dominant PSC stricture — brush cytology, FISH (fluorescence in situ hybridisation) during ERCP. PSC is the leading risk factor for CCA.
Key point
PSC: annual MRCP + CA19-9. CCA 10-15% lifetime risk. Dominant stricture = exclude CCA with brush cytology/FISH.
Question 4 · Dominant stricture in PSC
Correct answer: ERCP with balloon dilatation ± biliary stent. Brush cytology and FISH to exclude CCA. Antibiotics for cholangitis if present
Why
Dominant stricture in PSC: ERCP with balloon dilation (and stenting if needed). Critical: brush cytology + FISH for CCA cells (CCA risk high in PSC). If CCA confirmed: staging and surgical/oncological management. Biliary stenting relieves jaundice temporarily. Liver transplant: only curative option for PSC itself (not for CCA in most centres).
Key point
Dominant PSC stricture: ERCP dilation + stent + brush cytology + FISH (exclude CCA). CCA high risk in PSC.
Question 5 · IBD management in PSC
Correct answer: PSC-IBD: higher risk of colorectal cancer than UC alone. Annual colonoscopy surveillance recommended regardless of UC activity. Colectomy may also help liver disease
Why
PSC-IBD: UC associated with PSC carries higher CRC risk than UC alone (cumulative risk 30% at 20 years). Annual colonoscopy (not every 3-5 years as for standard UC) from diagnosis of PSC. Colectomy for UC in PSC does NOT reliably improve liver disease. After liver transplant for PSC: IBD may worsen.
Key point
PSC-IBD: annual colonoscopy (higher CRC risk than UC alone). Colectomy does not reliably improve liver disease.
Question 6 · Liver transplant in PSC
Correct answer: Liver transplant is the only curative treatment for PSC. Excellent outcomes — 5-year survival >85%. PSC can recur in transplanted liver (30-40% at 10 years)
Why
PSC + liver transplant: only curative treatment. Excellent outcomes (5-year survival >80-85%). Indication: advanced cirrhosis, recurrent cholangitis, decompensation. CCA: most centres consider unresectable CCA a contraindication (except selected centres with neoadjuvant chemoradiation protocols — Mayo Protocol). PSC recurrence in transplanted liver: 30-40% at 10 years.
Key point
PSC: liver transplant is curative. 5-year survival >85%. PSC can recur (30-40% at 10yr). CCA = relative contraindication.
Case complete
Practice on this page does not update your app progress. Open the browser app if you want its learning tools and progress record.